



NDA 021928/S-032, S-036, S-038

SUPPLEMENT APPROVAL

Pfizer, Inc.
235 E. 42nd Street
New York, NY 10017

Attention: Lilya I. Donohew, PhD
Senior Director, Worldwide Regulatory Affairs

Dear Dr. Donohew:

Please refer to your Supplemental New Drug Applications (sNDAs) dated and received October 24, 2013(S-032), April 8, 2014 (S-036), and September 3, 2014 (S-038), submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Chantix (varenicline) Tablets; 0.5 mg and 1 mg.

We acknowledge receipt of your amendments dated November 8, and December 20, 2013, April 30, and September 18, 2014 (S-032), April 29, May 2, 5, and 8, August 1, and September 18, 2014 (S-036), and September 3, and 18, 2014 (S-038), and your proposed risk evaluation and mitigation strategy (REMS) modification dated November 8, 2013 (S-032) and September 3, 2014 (S-038).

We also refer to our letter dated August 6, 2014, notifying you, under Section 505(o)(4) of the FDCA, of new safety information that we believe should be included in the labeling for Chantix. This information pertains to the risk of seizures and the potentiation of the intoxicating effects of alcohol.

Finally we refer you to our September 4, 2013, and August 6, 2014, letters notifying you, under section 505-1(g)(4)(B) of the FDCA, that your REMS must be modified based on findings from your 18-month REMS assessment and the new safety information described above.

Supplement S-032 proposes revisions to the **DRUG INTERACTIONS** section of the Package Insert regarding a potential interaction between alcohol and varenicline and includes a proposed modification to the approved risk evaluation and mitigation strategy (REMS), including revisions to the Medication Guide and revisions to the Chantix REMS goal.

Supplement S-036 proposes changes to the Package Insert based on meta-analyses of varenicline clinical trials and published observational studies pertaining to serious neuropsychiatric events.

Supplement S-038 proposes revisions to the labeling for Chantix. The agreed upon changes to the language included in our August 6, 2014, letter are included in the appended labeling text.

S-038 also includes additional proposed modifications to the approved risk evaluation and mitigation strategy (REMS), comprising further revisions to the Medication Guide as well as revisions to the Chantix REMS goal.

APPROVAL & LABELING

We have completed our review of these supplemental applications, as amended, and they are approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling(text for the package insert and Medication Guide), with the addition of any labeling changes in pending “Changes Being Effectuated” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that includes labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

We request that the labeling approved today be available on your website within 10 days of receipt of this letter.

RISK EVALUATION AND MITIGATION STRATEGY (REMS)

The REMS for Chantix (varenicline) was originally approved on October 19, 2009, and the most recent modification was approved on July 22, 2011. The REMS consists of a Medication Guide and a timetable for submission of assessments of the REMS. Your proposed modifications to the REMS consist of revisions to the Medication Guide to describe the risk of seizures and the potentiation of the intoxicating effects of alcohol, and revise the “What is the most important

information I should know about CHANTIX” section of the Medication Guide as well as other sections of the Medication Guide so as to furnish adequate information for the safe and effective use of the drug. In addition, the proposed modification includes revisions to the Chantix REMS goal to focus only on neuropsychiatric risks.

Your proposed modified REMS, submitted on September 3, 2014, and appended to this letter, is approved.

The modified REMS consists of a Medication Guide and a timetable for submission of assessments of the REMS.

The timetable for submission of assessments of the REMS will remain the same as that approved on October 19, 2009.

There are no changes to the REMS assessment plan described in our October 19, 2009, letter.

In addition to the assessments submitted according to the timetable included in the approved REMS, you must submit a REMS assessment and may propose a modification to the approved REMS when you submit a supplemental application for a new indication for use as described in section 505-1(g)(2)(A) of the FDCA.

If the assessment instruments and methodology for your REMS assessments are not included in the REMS supporting document, or if you propose changes to the submitted assessment instruments or methodology, you should update the REMS supporting document to include specific assessment instrument and methodology information at least 90 days before the assessments will be conducted. Updates to the REMS supporting document may be included in a new document that references previous REMS supporting document submission(s) for unchanged portions. Alternatively, updates may be made by modifying the complete previous REMS supporting document, with all changes marked and highlighted. Prominently identify the submission containing the assessment instruments and methodology with the following wording in bold capital letters at the top of the first page of the submission:

**NDA 021928 REMS CORRESPONDENCE
(insert concise description of content in bold capital letters, e.g.,
UPDATE TO REMS SUPPORTING DOCUMENT - ASSESSMENT
METHODOLOGY)**

Prominently identify the submission containing the REMS assessments or proposed modifications of the REMS with the following wording in bold capital letters at the top of the first page of the submission as appropriate:

**NDA 021928 REMS ASSESSMENT

NEW SUPPLEMENT FOR NDA 021928
PROPOSED REMS MODIFICATION**

**NEW SUPPLEMENT (NEW INDICATION FOR USE)
FOR NDA 021928
REMS ASSESSMENT
PROPOSED REMS MODIFICATION (if included)**

If you do not submit electronically, please send 5 copies of REMS-related submissions.

An authorized generic drug under this NDA must have an approved REMS prior to marketing. Should you decide to market, sell, or distribute an authorized generic drug under this NDA, contact us to discuss what will be required in the authorized generic drug REMS submission.

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit the following, in triplicate, (1) a cover letter requesting advisory comments, (2) the proposed materials in draft or mock-up form with annotated references, and (3) the package insert(s) to:

Food and Drug Administration
Center for Drug Evaluation and Research
Office of Prescription Drug Promotion (OPDP)
5901-B Ammendale Road
Beltsville, MD 20705-1266

You must submit final promotional materials and package insert(s), accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at

<http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf>.

Information and Instructions for completing the form can be found at

<http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf>. For more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see <http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm>.

All promotional materials that include representations about your drug product must be promptly revised to be consistent with the labeling changes approved in this supplement, including any new safety information [21 CFR 314.70(a)(4)]. The revisions in your promotional materials should include prominent disclosure of the important new safety information that appears in the revised package labeling. Within 7 days of receipt of this letter, submit your statement of intent to comply with 21 CFR 314.70(a)(4) to the address above or by fax to 301-847-8444.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Ayanna Augustus, PhD, RAC, Sr. Regulatory Project Manager, at (301) 796-3980.

Sincerely,

{See appended electronic signature page}

Judith A. Racoosin, MD, MPH
Deputy Director for Safety
Division of Anesthesia, Analgesia and
Addiction Products
Office of Drug Evaluation II
Center for Drug Evaluation and Research

ENCLOSURE(S):
Content of Labeling
REMS

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

JUDITH A RACOOSIN
09/19/2014